Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Nvidia Secures $500 Billion AI Infrastructure Push With Wall Street Giants 
Anthropic Signs $9.1B AI Data Center Deal With Riot Platforms 
US Tightens Ebola Controls as Congo Outbreak Sparks Global Concern 
FDA Investigates New Cyclospora Outbreak as U.S. Cases Continue to Rise 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent 
Hanwha Offers Up to $1.2 Billion for Austal US Business 
Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings 
US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Pharmaceutical giants are pivoting toward direct-to-consumer sales and offering steep drug discounts in the United States after President Donald Trump called for lower prescription prices and reduced reliance on “middlemen” such as insurers and pharmacy benefit managers. The move comes ahead of the Trump administration’s planned TrumpRx.gov launch in early 2026 — a federal website that will feature reduced drug prices.
U.S. patients currently pay nearly three times more for medicines than those in other developed countries. Following Trump’s July letters to 17 major firms demanding price cuts, several have responded with new pricing and sales models.
AbbVie announced it will launch its ovarian cancer drug Elahere in the UK at the same U.S. price, aligning with Trump’s “most-favored-nation” pricing policy. AstraZeneca struck a deal with the administration to sell select drugs at steep discounts through Medicaid and TrumpRx.gov, with up to 80% price reductions on some medicines. Bristol-Myers Squibb will cut prices on its blood clot drug Eliquis and plaque psoriasis treatment Sotyktu.
Eli Lilly began shipping high-dose Zepbound directly to consumers, while Novo Nordisk partnered with telehealth providers like GoodRx, Hims & Hers, and Ro to offer Ozempic and Wegovy to cash-paying patients. Pfizer also agreed to lower Medicaid prices to match global rates and will invest $70 billion in U.S. R&D in return for tariff relief.
Sanofi introduced a $35 monthly insulin cap for all U.S. patients, and Roche is exploring direct sales to consumers. Women’s telehealth platform Wisp expanded to offer weight-loss drugs from Eli Lilly and Novo Nordisk with home delivery. Zealand Pharma is also weighing a similar model for its experimental obesity treatment.
Industry group PhRMA plans to launch AmericasMedicines.com in January, helping patients buy directly from manufacturers — signaling a major shift toward affordability and accessibility in the U.S. drug market.
